{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["nivolumab","radium-223"]],"indication":"metastatic castration-resistant prostate cancer","name":"Rad2Nivo","nct_id":"NCT04109729","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=rad2nivo-nct04109729. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"Rad2Nivo","arms":[{"description":"Radium-223 kBq/kg IV every 4 weeks for up to 6 doses. Nivolumab 480 mg IV every 4 weeks for up to 2 years.","label":"All patients","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-12","type":"ESTIMATED"},"conditions":["Metastatic Castration-resistant Prostate Cancer"],"enrollment":{"count":39,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Nivolumab","otherNames":["Opdivo"],"type":"DRUG"},{"name":"Radium-223","otherNames":["Xofigo"],"type":"DRUG"}],"last_update":"2026-06-01","lead_sponsor":"University of Utah","official_title":"A Phase IB Study of Nivolumab in Combination With Radium-223 in Men With Metastatic Castration Resistant Prostate Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2026-04-28","type":"ACTUAL"},"primary_outcomes":[{"measure":"To assess the frequency of grade 3 or greater non-hematologic treatment-emergent adverse events when combining nivolumab with Radium-223","timeFrame":"From cycle one day one until cycle 3 day 28 (each cycle is 28 days) - approximately 12 weeks"},{"measure":"To assess the ctDNA reduction after 6 weeks of nivolumab treatment.","timeFrame":"From cycle one day one until cycle 4 day 15 (each cycle is 28 days) - approximately 14 weeks"}],"references":[],"start_date":{"date":"2020-09-16","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT04109729"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/rad2nivo-nct04109729"}